Vital Signs - Advances in Cancer Treatment, Clampdown on Specialty Pharmacies and Strategy Revamp for Sequencing Provider, An Analysis

Liquid Biopsy Test for Prostate Cancer and Non-small Cell Lung Cancer Treatment Show Promise

USD 450

* Required Fields

USD 450

PAY BY INVOICE

Be the first to review this product

This issue of Vital Signs discusses MDxHealth's launch of the SelectMDx Liquid Biopsy Test in Europe, the FDA's approval of a new treatment for non-small cell lung cancer with EGFR mutations, the clamp down on specialty pharmacies by US drug benefit managers, and BGI's strategy redirection for Complete Genomics.

Table of Contents

Vital Signs - Advances in Cancer Treatment, Clampdown on Specialty Pharmacies and Strategy Revamp for Sequencing Provider, An Analysis Vital Signs - November 2015 IssueNovember Issue




Related Research

Release Date : 19-May-17

Region : Global

Release Date : 12-May-17

Region : Global

Release Date : 12-May-17

Region : Global

Release Date : 12-May-17

Region : Global

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.